Chemung Canal Trust Co. acquired a new position in shares of Sanofi (NYSE:SNY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,585 shares of the company’s stock, valued at approximately $268,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC purchased a new position in Sanofi during the first quarter worth approximately $113,000. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the period. BLB&B Advisors LLC purchased a new position in Sanofi during the first quarter worth approximately $202,000. Huntington National Bank raised its position in Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock worth $202,000 after buying an additional 147 shares during the period. Finally, New England Research & Management Inc. purchased a new position in Sanofi during the first quarter worth approximately $208,000. Institutional investors own 9.96% of the company’s stock.
Sanofi (NYSE:SNY) traded up 0.30% on Friday, hitting $47.55. 717,957 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $47.99 and a 200-day moving average price of $46.11. The stock has a market cap of $119.42 billion, a P/E ratio of 11.23 and a beta of 0.88. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24.
Sanofi (NYSE:SNY) last posted its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. The business had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. Sanofi’s revenue was down 2.3% compared to the same quarter last year. Equities analysts predict that Sanofi will post $3.26 earnings per share for the current fiscal year.
SNY has been the subject of a number of analyst reports. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. BidaskClub upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Argus raised their target price on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Friday, June 2nd. Finally, Berenberg Bank downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $63.75.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.